IMPORTANCE Updated estimates of the prevalence and incidence rates of low vision and blindness are needed to inform policy makers and develop plans to meet the future demands for low vision rehabilitation services.
L ow vision (LV) and blindness are leading causes of disability among US residents. 1, 2 Updated estimates of the prevalence of blindness and LV were recently reported using population-based studies applied to current US census data. 3 However, the incidence of blindness and LV in the United
States was formally estimated more than a decade ago using 2000 census data. [4] [5] [6] More current and detailed estimates are needed to inform policy makers to adequately meet present and growing demands for LV rehabilitation services. The World Health Organization defines LV as a bestcorrected visual acuity (BCVA) in the better-seeing eye of less than 20/60. 7 Many programs, like Medicare, 8 use this standard, but considerable evidence (plus the American Academy of Ophthalmology Preferred Practice Patterns 9 ) supports the consensus that people experience functional limitations when the BCVA in the better-seeing eye is less than 20/40. 3, 5, [10] [11] [12] Legal blindness is defined as a BCVA of 20/200 or less by the US Social Security Administration with a modified definition of less than 20/100 when measured with modern visual acuity charts. 13 The World Health Organization defines blindness as a visual acuity of less than 20/400. 7 The term visual impairment applies to any individual presenting with vision loss, which may encompass uncorrected refractive error. Because most LV cases are caused by age-related eye diseases, the number of individuals with LV will increase along with the aging of the US population. For the purposes of policy planning and identifying LV care demand, however, it is more important to know the number of new cases each year. Setting up programs on the basis of prevalence alone would address only the backlog of individuals with LV. Therefore, continued service provision relies on the incidence. The most recent estimates of the prevalence and incidence of LV and blindness as a function of age used meta-analyses. 3, 5 The weakness of this approach is that the results of multiple epidemiological studies (some more than 30 years old) are merged. The present study takes advantage of presenting visual acuity (PVA) and BCVA raw data, which were collected as part of the most recent (2007) (2008) ) National Health and Nutrition Examination Survey (NHANES). The NHANES data on the prevalence of correctable and uncorrectable visual impairment are a function of age, sex, race and ethnicity, and a variety of other personal and demographic traits. Vitale et al 6 used data from the 1999-2002 NHANES combined with the 2000 US census data to estimate the total prevalence of correctable and uncorrectable visual impairment in the United States. The purpose of the present study is to provide updated estimates of the prevalence of LV and blindness for different age groups in the United States and develop models of LV prevalence and annual incidence rates as a function of age for the different visual acuity criteria commonly used to define LV and legal blindness.
Methods
The NHANES is a cross-sectional sample of the noninstitutionalized US population and is a program of ongoing surveys of health status performed in 2-year cycles by the National Cen- In the NHANES, PVA was measured for each eye while participants used their usual distance vision correction, if any. Visual acuity was measured using an autorefractor The NHANES measured PVA and BCVA in a sample of 6016 people. Many epidemiological LV studies use an age of 50 years or older as the criterion for adults, but this study included individuals 45 years of age or older. The rationale was that a data point close to the asymptote improves the estimate of the model parameters. Five-year intervals were used, and values were assigned to the midpoint of the data. Including the age category of 45 years allowed the use of the midpoint age of 47.5 years rather than 52.5 years, the midpoint for starting with age 50 years. Those without complete BCVA data were excluded. Age was reported to the nearest year. For the purpose of the present analysis, LV was defined in 2 ways: a BCVA in the betterseeing eye of less than 20/40 and a BCVA of less than 20/60. Meaning Prevalence and incidence rates show a substantial increase in the need for low vision rehabilitation services with the aging of the US population.
(NHW); Hispanic white (HW); and total black (TB), which combined Hispanic and non-Hispanic black. All other racial/ ethnic groups had too few individuals in the sample to analyze separately. The number of persons as a function of age was counted for each of the visual acuity categories in the 3 racial/ ethnic groups. The TB and HW groups are overrepresented in the NHANES sample, and the NHW group is underrepresented relative to their distribution in the US population. Therefore, the LV prevalence for the NHANES subsamples in each age group was weighted to correct the sample biases in racial/ ethnic groups. 10 The weighted observed prevalence for each group was combined in each age bin for each visual acuity category and then divided by the corresponding weighted total sample size to obtain an estimated prevalence rate as a function of age representative of the total population. For all visual acuity categories, the prevalence rate appeared to be an exponential function of age; that is, the log e prevalence rate should be linear with age for all visual acuity categories.
To determine the incidence of LV and blindness in the US population, the exponential model was linearized by estimating the log e prevalence rate vs age for older adults (≥45 years). These estimates used each visual acuity data set. (Data were omitted for ages at which the empirical prevalence rate is 0 because the corresponding log e is undefined.) The rate of change in log e prevalence was assumed to be the same for each visual acuity range; therefore, the model rate constant was calculated from linear regression of the log e prevalence rate (corrected for differences between visual acuity category intercepts) vs age for each visual acuity data set. The exponential model with a fixed rate constant (ie, slope of the log e regression model) was then used to refine the estimates of the visual acuity-specific coefficient (ie, intercept of the log e regression model) because empirical prevalence rates of 0 could be used in the nonlinear regression analyses.
The use of the exponential model presumes that (1) once an individual has LV, visual acuity does not improve over time, and (2) the rate of change in prevalence rate is a constant percentage of the prevalence rate (ie, prevalence grows by adding new cases over time to the existing pool of cases). However, we were interested not only in the growth of the prevalence rate with time but also in the percentage of new cases annually for each age group (ie, the incidence rate). To estimate the incidence rate, the growth of the prevalence rate vs age must be corrected by accounting for the percentage of individuals in the pool who die (death rate vs age). The following equations illustrate how these assumptions were incorporated in the models.
The exponential LV prevalence rate model is defined by the equation p(t) = exp (rt + b VA ), where t is the person's age in years; r is the rate constant (slope of the linear regression on log e prevalence rate vs age), which is constrained to be the same for all 3 visual acuity criteria for LV; and b VA is a visual acuityspecific coefficient (intercept of the linear regression on log e prevalence rate vs age).
These models of prevalence rate were differentiated by age to estimate the annual growth rates in LV prevalence for each of the 3 BCVA criteria as a function of age:
The rate of growth in prevalence rate, p′(t), includes the rate of new LV cases less the mortality rate of existing LV cases. Thus, to calculate the annual LV incidence rate (ie, the number of new cases of LV each year), i(t), adding back in the LV mortality rate, p(t)m(t), is necessary: Figure 1 illustrates estimates of annual mortality rates for the US population as a function of age in 2010 (solid circles). 15 The curve fit to the mortality rate estimates is the exponential function m(t)=6 × 10 −5 exp (0.082t), in which t refers to age.
The mean of the slopes of the regression lines fit to log e prevalence rate vs age data for 3 different BCVA categories: (<20/40 to 20/60, <20/60 to >20/200, and ≤20/200) is 0.087 ( Figure 2) . To display the data together with the regression line The solid line is log e prevalence rate vs age with the slope fixed to 0.087 for all BCVA levels. This figure illustrates how well the model fits the 3 data sets after the data are adjusted to equate the intercepts.
having the average slope, the intercept for the regression on the data set of less than 20/40 to 20/60 BCVA was used as the reference, and the log e prevalence rates for the 2 other BCVA categories were adjusted to ensure that their respective regression line intercepts matched the reference. The Using methods similar to those used by Vitale et al, 6 we calculated the prevalence of presenting correctable and uncorrectable visual impairment over the entire age range from the NHANES samples for children (<18 years), young adults (18-44 years), and older adults (≥45 years). Prevalence rates of PVA and BCVA were estimated from the 2007-2008 NHANES data sets and were broken down and weighted according to racial/ethnic representation in each age group.
Results
The 2017 estimated prevalence rates of LV for older adults (≥45 The results of the nonlinear regression analyses of LV prevalence rate vs age are illustrated for the different BCVA criteria in Figure 3 along with the estimated prevalence rate data, plotted at the midpoint of each 5-year age category. The dashed curves in Figure 3 define the model boundaries from the 95% CI, calculated from ±1.96 SEs for each exponential function representing an LV or legal blindness category.
The overall prevalence rates of LV and legal blindness were estimated for 3 broad age categories (<18 years, 18-44 years, and ≥45 years) for each of the 3 BCVA categories (<20/40, <20/ 60, and ≤20/200). Table 2 lists the estimated prevalence rates in each BCVA category, racial/ethnic category, and age category, organized by participants' PVA in the better-seeing eye and BCVA in the better-seeing eye. Table 2 also lists the percentage of people in each category whose PVA could be improved to 20/40 or greater by correcting refractive error. The racial/ethnic categories, organized by age groups and by BCVA criterion, give us 27 comparisons to assess for significance. A Bonferroni correction for α = .05 gives the criterion of a sta- Table 1 lists the estimated prevalence and annual incidence of low vision for adults 45 years of age or older in the US population for each visual criterion projected for 2017, 2030, and 2050 from the 2010 US census data by age. Table 1 also lists the estimated prevalence of low vision in the total population (including younger individuals) for each visual criterion projected for 2017, 2030, and 2050 from the 2010 US census data by age. Incidence estimates were not calculated in the younger age group owing to the small number of individuals in some categories.
Discussion
Overall, the youngest group (<18 years) had the highest rate of presenting visual impairment in the better-seeing eye for all 3 BCVA categories. Similar to the results obtained by Vitale et al, 6 findings from our study indicate that 85% to 96% of children with presenting visual impairments could have their BCVA corrected to greater than 20/40. Because most causes of permanent impairment increase in prevalence with increasing age, the highest rates of nonrefractive LV and blindness were seen in older individuals. Presenting visual impairment was greatest in the HW and TB racial/ethnic categories; however, those groups also demonstrated a higher rate of visual impairment that could be corrected with spectacles to 20/40 or greater BCVA. No significant differences were detected between racial/ethnic categories (after Bonferroni correction), with the exception of the 3 comparisons mentioned earlier. These findings are consistent with previous reports that NHW individuals represent the largest number of people with LV and blindness. 3 Ko et al 11 reported
that the factors associated with nonrefractive visual impairment included older age, poverty, lower educational level, and diabetes diagnosed 10 or more years ago. However, increasing rates of visual impairment in younger individuals may be attributed to an increase in systemic illness and a lack of health care, which may identify the need for myopic correction. The current prevalence rate estimates are similar to previously reported rates. 4, 5 Figure 3 compares the estimates of prevalence rate vs age by Congdon et al 5 with those of the present study, along with the exponential model we propose. Earlier estimates of prevalence rates as a function of age drew summary data from different studies that used differing BCVA criteria and age category definitions. The present study used updated census data, with age in the database specified in 1-year increments, and therefore may provide more precise estimates. In addition, visual acuity was measured the same way for all participants in the NHANES data set and specified to the nearest line. Numerous assumptions and approximations had to be made in the previous meta-analyses, but there is remarkable quantitative agreement between the studies.
To build our models, we assumed that LV does not increase the risk of death and applied the mortality rate as a function of age from the general population to the LV population. However, an increased risk of mortality has been shown in cases of patient-reported severe bilateral visual impairment. 17 In addition, it is possible, if not probable, that LV increases death rates because LV increases the risk of falls, 18-22 medication mismanagement, 23, 24 and reduced activity levels. [24] [25] [26] [27] [28] If the death rate has been underestimated for the LV population, then the annual LV incidence rate also has been underestimated. The risk of age-related eye disease increases with increasing age, 5, 28, 29 which explains the acceleration of the LV prevalence rate with age ( Figure 3 ).
Limitations
This study had several limitations. The NHANES vision screening data did not provide visual acuity measurements between 20/80 and 20/200. Therefore, the legal blindness definition was limited to 20/200 or less visual acuity in the betterseeing eye. Individuals with profound visual impairment (hand motions, light perception, or no light perception) were excluded from visual acuity testing but were included in the BCVA category of less than 20/200; with refraction, some of these people may have had BCVA improvement. Because autorefraction was used to determine corrected visual acuity, it is possible that refractive error was not fully corrected for all participants, potentially contributing to an overestimation of uncorrectable visual acuity loss. The sample contained some racial/ethnic groups with too few individuals to include in the analyses. By design, the NHANES does not include people who are institutionalized (eg, nursing home population); therefore, the prevalence and annual incidence of visual acuity loss in the population were likely underestimated. In addition, NHANES vision screening data did not provide data on visual fields. Patients with visual field loss, with relatively intact visual acuity, would not be included in the visual impairment estimates. Estimates of LV and blindness were based on projections from the census data, which did not specify ocular conditions (such as the rate of myopia) or identify visual impairment associated with systemic diseases (such as diabetes). Therefore, the incidence and prevalence of LV and blindness estimated in this study are likely to be too low.
Conclusions
The exponential growth in prevalence rate vs age reflects the increased risk of vision loss from age-related eye disease with each passing year. As demonstrated in Tables 1 and 2 , assuming the prevalence and mortality rates stay constant, we expect a greater need for services for those patients with LV as the aging population increases over the next several decades. Regarding health care delivery, prevalence rates can be used to estimate the backlog of people with visual impairment needing LV services. However, of likely greater relevance for planning purposes and provision of health care services is the number of new cases of visual impairment and blindness each year, which is estimated by the annual incidence for older adults: more than 480 000 cases of mild LV or worse (<20/40), more than 180 000 cases of moderate LV or worse (<20/60), and more than 134 000 legally blind cases (≤20/200). In addition, consistent with prior studies, data suggest that vision screenings for uncorrected refractive error could substantially reduce the prevalence of visual impairment.
